

METHODS AND MATERIALS FOR GALGT2 GENE THERAPY

Statement of Government Interest

[0001] This invention was made with government support under U54 NS055959 and R01 AR049722 awarded by the National Institutes of Health. The government has certain rights in the invention.

Incorporation by Reference of the Sequence Listing

[0002] This application contains, as a separate part of disclosure, a Sequence Listing in computer-readable form (filename: 49885PCT_Seqlisting.txt; 14,467 bytes – ASCII text file; created September 15, 2016) which is incorporated by reference herein in its entirety.

Field

[0003] The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a GALGT2 polynucleotide. The disclosure provides rAAV and methods of using the rAAV for GALGT2 gene therapy of neuromuscular disorders. Exemplary neuromuscular disorders include, but are not limited, to muscular dystrophies such as Duchenne muscular dystrophy, Congenital Muscular Dystrophy 1A and Limb Girdle Muscular Dystrophy 2D.

Background

[0004] Muscular dystrophies (MDs) are a group of genetic diseases. The group is characterized by progressive weakness and degeneration of the skeletal muscles that control movement. Some forms of MD develop in infancy or childhood, while others may not appear until middle age or later. The disorders differ in terms of the distribution and extent of muscle weakness (some forms of MD also affect cardiac muscle), the age of onset, the rate of progression, and the pattern of inheritance.

[0005] One type of MD is Duchenne muscular dystrophy (DMD). It is the most common severe childhood form of muscular dystrophy affecting 1 in 5000 newborn males. Inheritance follows an X-linked recessive pattern. DMD is caused by mutations in the DMD gene leading to absence of dystrophin protein (427 KDa) in skeletal and cardiac muscles, as well as GI tract and retina. Dystrophin not only protects the sarcolemma from eccentric contractions, but also anchors a number of signaling proteins in close proximity to sarcolemma. Clinical symptoms of DMD are usually first noted between ages 3 to 5 years, with altered gait and reduced motor skills typically leading to diagnostic evaluation. DMD is relentlessly progressive, with loss of

ambulation by age twelve. Historically patients died from respiratory complications late in the second decade, but improved supportive care – and in particular judicious use of nocturnal ventilatory support – has extended life expectancy by nearly a decade. Prolonging life unmasks the nearly universal decline in cardiac function, with complications of dilated cardiomyopathy. This poses further clinical challenges and a need for recognition and medical intervention that did not previously exist. Non-progressive cognitive dysfunction may also be present in DMD. Despite virtually hundreds of clinical trials in DMD, treatment with corticosteroids remains the only treatment that has consistently demonstrated efficacy. Current standard of care for DMD involves use of prednisone or deflazacort, which can prolong ambulation by several years at the expense of significant side effects, and has limited evidence for any impact on survival.

[0006] Another type of MD is Congenital Muscular Dystrophy 1A (MCD1A). MCD1A belongs to a group of neuromuscular disorders with onset at birth or infancy characterized by hypotonia, muscle weakness and muscle wasting. MCD1A represents 30-40% of congenital muscular dystrophies, with some regional variation. Prevalence is estimated at 1/30,000. The disease presents at birth or in the first few months of life with hypotonia and muscle weakness in the limbs and trunk. Respiratory and feeding disorders can also occur. Motor development is delayed and limited (sitting or standing is only possible with help). Infants present with early rigidity of the vertebral column, scoliosis, and respiratory insufficiency. There is facial involvement with a typical elongated myopathic face and ocular ophthalmoplegia disorders can appear later. Epileptic attacks are possible, although they occur in less than a third of subjects. Intellectual development is normal. MCD1A is caused by mutations in the LAMA2 gene coding for the alpha-2 laminin chain. Transmission is autosomal recessive. Current treatment is symptomatic. It consists of a multidisciplinary approach, including physiotherapists, occupational therapists and speech-language therapists, with the objective of optimizing each subject's abilities. Seizures or other neurological complications require specific treatment. The prognosis of MCD1A is very severe as a large proportion of affected children do not reach adolescence. Currently, the prognosis can only be improved by attentive multidisciplinary (particularly orthopedic and respiratory) management.

[0007] Yet another type of MD is Limb Girdle Muscular Dystrophy (LGMD). LGMDs are rare conditions and they present differently in different people with respect to age of onset, areas of muscle weakness, heart and respiratory involvement, rate of progression and severity. LGMDs can begin in childhood, adolescence, young adulthood or even later. Both genders are

affected equally. LGMDs cause weakness in the shoulder and pelvic girdle, with nearby muscles in the upper legs and arms sometimes also weakening with time. Weakness of the legs often appears before that of the arms. Facial muscles are usually unaffected. As the condition progresses, people can have problems with walking and may need to use a wheelchair over time. The involvement of shoulder and arm muscles can lead to difficulty in raising arms over head and in lifting objects. In some types of LGMD, the heart and breathing muscles may be involved.

[0008] There are at least nineteen forms of LGMD, and the forms are classified by their associated genetic defects.

Type	Pattern of Inheritance	Gene or Chromosome
LGMD1A	Autosomal dominant	Myotilin gene
LGMD1B	Autosomal dominant	Lamin A/C gene
LGMD1C	Autosomal dominant	Caveolin gene
LGMD1D	Autosomal dominant	Chromosome 7
LGMD1E	Autosomal dominant	Desmin gene
LGMD1F	Autosomal dominant	Chromosome 7
LGMD1G	Autosomal dominant	Chromosome 4
LGMD1H	Autosomal dominant	Chromosome 3
LGMD2A	Autosomal recessive	Calpain-3 gene
LGMD2B	Autosomal recessive	Dysferlin gene
LGMD2C	Autosomal recessive	Gamma-sarcoglycan gene
LGMD2D	Autosomal recessive	Alpha-sarcoglycan gene
LGMD2E	Autosomal recessive	Beta-sarcoglycan gene
LGMD2F	Autosomal recessive	Delta-sarcoglycan gene
LGMD2G	Autosomal recessive	Telethonin gene
LGMD2H	Autosomal recessive	TRIM32
LGMD2I	Autosomal recessive	FKRP gene
LGMD2J	Autosomal recessive	Titin gene
LGMD2K	Autosomal recessive	POMT1 gene
LGMD2L	Autosomal recessive	Fukutin gene
LGMD2M	Autosomal recessive	Fukutin gene
LGMD2N	Autosomal recessive	POMT2 gene
LGMD2O	Autosomal recessive	POMGnT1 gene

LGMD2Q

Autosomal recessive

Plectin gene

[0009] Specialized tests for LGMD are now available through a national scheme for diagnosis, the National Commissioning Group (NCG).

[0010] The GALGT2 gene (otherwise known as B4GALNT2) encodes a β 1-4-N-acetyl-D-galactosamine (β GalNAc) glycosyltransferase. GALGT2 overexpression has been studied in three different models of muscular dystrophy: DMD, LGMD2D and MDC1A [Xu *et al.*, *Am. J. Pathol.*, 175: 235-247 (2009); Xu *et al.*, *Am. J. Pathol.*, 171: 181-199 (2007); Xu *et al.*, *Neuromuscul. Disord.*, 17: 209-220 (2007); Martin *et al.*, *Am. J. Physiol. Cell. Physiol.*, 296: C476-488 (2009); and Nguyen *et al.*, *Proc. Natl. Acad. Sci. USA*, 99: 5616-5621 (2002)]. GALGT2 overexpression in skeletal muscles has been reported to induce the glycosylation of alpha dystroglycan with β 1-4-N-acetyl-D-galactosamine (GalNAc) carbohydrate to make the CT carbohydrate antigen (Neu5Ac/Gc α 2-3[GalNAc β 1-4]Gal β α 1-4GlcNAc β -). The GALGT2 glycosyltransferase and the CT carbohydrate it creates are normally confined to neuromuscular and myotendinous junctions in skeletal muscles of adult humans, non-human primates, rodents and all other mammals yet studied [Martin *et al.*, *J. Neurocytol.*, 32: 915-929 (2003)]. Overexpression of GALGT2 in skeletal muscle has been reported to stimulate the ectopic glycosylation of the extrasynaptic membrane, stimulating the ectopic overexpression of a scaffold of normally synaptic proteins that are orthologues or homologues of proteins missing in various forms of muscular dystrophy, including dystrophin surrogates (*e.g.*, utrophin, Plectin1) and laminin α 2 surrogates (laminin α 5 and agrin) [Xu *et al.* 2009, *supra*; Xu *et al.*, *Am. J. Pathol.* 2007, *supra*; Xu *et al.*, *Neuromuscul. Disord.* 2007, *supra*; Nguyen *et al.*, *supra*; Chicoine *et al.*, *Mol. Ther.*, 22: 713-724. (2014). As a group, the induction of such surrogates by GALGT2 has been reported to strengthen sarcolemmal membrane integrity and prevent muscle injury in dystrophin-deficient muscles as well as in wild type muscles [Martin *et al.*, *supra*]. GALGT2 overexpression in skeletal muscle has been reported to prevent muscle damage and inhibit muscle disease. This is true in the mdx mouse model for DMD [Xu *et al.*, *Neuromuscul. Disord.* 2007, *supra*; Martin *et al.* (2009), *supra*; Nguyen *et al.*, *supra*], where improvement equal to that of micro-dystrophin gene transfer is noted even though only half the number of fibers were transduced [Martin *et al.* (2009), *supra*]. Notably, GALGT2 gene transfer has also been reported to be preventive in the dy^w model for congenital muscular dystrophy 1A [Xu *et al.*, *Am. J. Pathol.*

2007, *supra*] and the *Sgca*^{-/-} mouse model for limb girdle muscular dystrophy type 2D [Xu *et al.* 2009, *supra*].

[0011] Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including 145 nucleotide inverted terminal repeat (ITRs). There are multiple serotypes of AAV. The nucleotide sequences of the genomes of the AAV serotypes are known. For example, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-2 is provided in GenBank Accession No. NC_001401 and Srivastava *et al.*, *J. Virol.*, 45: 555-564 (1983); the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the AAV-5 genome is provided in GenBank Accession No. AF085716; the complete genome of AAV-6 is provided in GenBank Accession No. NC_001862; at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively; the AAV-9 genome is provided in Gao *et al.*, *J. Virol.*, 78: 6381-6388 (2004); the AAV-10 genome is provided in *Mol. Ther.*, 13(1): 67-76 (2006); and the AAV-11 genome is provided in *Virology*, 330(2): 375-383 (2004). Cis-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the AAV ITRs. Three AAV promoters (named p5, p19, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes. The two rep promoters (p5 and p19), coupled with the differential splicing of the single AAV intron (at nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome. The cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, *Current Topics in Microbiology and Immunology*, 158: 97-129 (1992).

[0012] AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells allowing the possibility of targeting many different tissues *in vivo*.

Moreover, AAV transduces slowly dividing and non-dividing cells, and can persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in plasmids which makes construction of recombinant genomes feasible. Furthermore, because the signals directing AAV replication, genome encapsidation and integration are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA. The rep and cap proteins may be provided in trans. Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56° to 65°C for several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.

[0013] An AAV termed rh.74 has been used to deliver DNAs encoding various proteins. Xu et al., *Neuromuscular Disorders*, 17: 209-220 (2007) and Martin et al., *Am. J. Physiol. Cell. Physiol.*, 296: 476-488 (2009) relate to rh.74 expression of cytotoxic T cell GalNAc transferase for Duchenne muscular dystrophy. Rodino-Klapac et al., *Mol. Ther.*, 18(1): 109-117 (2010) describes AAV rh.74 expression of a micro-dystrophin FLAG protein tag fusion after delivery of the AAV rh.74 by vascular limb perfusion.

[0014] The muscular dystrophies are a group of diseases without identifiable treatment that gravely impact individuals, families, and communities. The costs are incalculable. Individuals suffer emotional strain and reduced quality of life associated with loss of self-esteem. Extreme physical challenges resulting from loss of limb function creates hardships in activities of daily living. Family dynamics suffer through financial loss and challenges to interpersonal relationships. Siblings of the affected feel estranged, and strife between spouses often leads to divorce, especially if responsibility for the muscular dystrophy can be laid at the feet of one of the parental partners. The burden of quest to find a cure often becomes a life-long, highly focused effort that detracts and challenges every aspect of life. Beyond the family, the community bears a financial burden through the need for added facilities to accommodate the handicaps of the muscular dystrophy population in special education, special transportation, and costs for recurrent hospitalizations to treat recurrent respiratory tract infections and cardiac complications. Financial responsibilities are shared by state and federal governmental agencies extending the responsibilities to the taxpaying community.

[0015] There thus remains a significant need in the art for treatments for neuromuscular disorders including, but not limited to, muscular dystrophies such as DMD, MDC1A and LGMD2D.

Summary

[0016] In one aspect, the present disclosure refers to a nucleic acid comprising, in order from 5' to 3': (i) a first AAV2 inverted terminal repeat sequence (ITR); (ii) an MCK enhancer comprising nucleotides 236-442 of SEQ ID NO: 2; (iii) a muscle creatine kinase core promoter sequence set out in nucleotides 443-793 of SEQ ID NO: 2; (iv) a nucleotide sequence encoding a human GALGT2 polypeptide comprising nucleotides 1002-2522 of SEQ ID NO: 2; and (v) a second AAV2 ITR sequence. In another aspect, the disclosure refers to a nucleic acid comprising an rAAV.rh74.MCK.GALGT2 genome that is at least 90% identical to the nucleotide sequence set out in SEQ ID NO: 2. In yet another aspect, the present disclosure refers to a nucleic acid comprising the rAAV.rh74.MCK.GALGT2 genome set out in SEQ ID NO: 2. In still another aspect, the present disclosure refers to a recombinant adeno-associated virus particle (rAAV) comprising the nucleic acid as claimed herein, wherein the rAAV is infectious. In another aspect, the present disclosure refers to a composition comprising the rAAV as claimed herein and a pharmaceutically acceptable carrier. In another aspect, the present disclosure refers to the use of the composition as claimed herein in the manufacture of a medicament for the treatment of a neuromuscular disorder, wherein the neuromuscular disorder is Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy; Congenital Muscular Dystrophy (MDC) 1A, 1B, 1C and 1D; Limb Girdle Muscular Dystrophy (LGMD) 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 2A, 2B, 2C, 2D, 2E, 2F, 2G 2H, 2I, 2J, 2K, 2L, 2M, 2N, 2O and 2Q; Bethlem Myopathy; Ullrich Congenital Muscular Dystrophy; Muscle Eye Brain Disease; Fukuyama Congenital Muscular Dystrophy; Walker Warburg Syndrome; Myotonic Dystrophy; Myasthenic syndromes; Congenital Myasthenias; Inclusion Body Myopathy; Inclusion Body Myositis; Emery Dreifuss Muscular Dystrophy; Distal Muscular Dystrophy; Dermatomyositis; Centronuclear Myopathy; Facioscapulohumeral Muscular Dystrophy; Myoshi Myopathy; Mitochondrial Myopathy; Nemaline Myopathy; Nonaka Myopathy; Myasthenia Gravis; or Polymyositis. In another aspect, the present disclosure refers to the use of the composition as claimed herein in the manufacture of a medicament for the treatment of a neuromuscular disorder, wherein the neuromuscular disorder is a muscular dystrophy. Further disclosed herein are methods of treating a neuromuscular disorder in a subject in need thereof in which a recombinant adeno-associated virus (rAAV) such as rAAVrh74.MCK.GALGT2 is administered to the subject, where: the route of administration is an intramuscular route and the dose of the rAAV administered is about 3×10^{11} vg/injection to about 5×10^{12} vg/injection, the route of administration is an intramuscular route and the dose of the rAAV administered is about 3×10^{11} vg/injection, the route of administration is an intramuscular route and the dose of the rAAV administered is about 1×10^{12} vg/injection, the route of administration is an intramuscular route and the dose of the rAAV administered is about 5×10^{12} vg/injection, the route of administration is inter-arterial limb perfusion and the dose of the rAAV administered is about 6×10^{12} vg/kg/limb to about 4.8×10^{13} vg/kg/limb, the route of administration is inter-arterial limb perfusion and the dose of the rAAV administered is about 6×10^{12} vg/kg/limb, the route of administration is inter-arterial limb perfusion and the dose of the rAAV administered is about 1.2×10^{13} vg/kg/limb, the route of administration is inter-arterial limb perfusion and the dose of the rAAV administered is about 2.4×10^{13} vg/kg/limb, the route of administration is inter-arterial limb perfusion and the

dose of the rAAV administered is about 4.8×10^{13} vg/kg/limb, the route of administration is systemic intravenous administration and the dose of the rAAV administered is about 2×10^{14} vg/kg to about 6×10^{15} vg/kg, the route of administration is systemic intravenous administration and the dose of the rAAV administered is about 4×10^{14} vg/kg to about 6×10^{15} vg/kg, the route of administration is systemic intravenous administration and the dose of the rAAV administered is about 4×10^{14} vg/kg, the route of administration is systemic intravenous administration and the dose of the rAAV administered is about 8×10^{14} vg/kg, the route of administration is systemic intravenous administration and the dose of the rAAV administered is about 2×10^{15} vg/kg or the route of administration is systemic intravenous administration and the dose of the rAAV administered is about 6×10^{15} vg/kg.

[0017] Examples of neuromuscular disorder for which treatment is contemplated are Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy; Congenital Muscular Dystrophy (MDC) 1A, 1B, 1C and 1D; Limb Girdle Muscular Dystrophy (LGMD) 1A, 1B, 1C,

1D, 1E, 1F, 1G, 1H, 2A, 2B, 2C, 2D, 2E, 2F, 2G 2H, 2I, 2J, 2K, 2L, 2M, 2N, 2O and 2Q; Bethlem Myopathy; Ullrich Congenital Muscular Dystrophy; Muscle Eye Brain Disease; Fukuyama Congenital Muscular Dystrophy; Walker Warburg Syndrome; Myotonic Dystrophy; Myasthenic syndromes; Congenital Myasthenias; Inclusion Body Myopathy; Inclusion Body Myositis; Emery Dreifuss Muscular Dystrophy; Distal Muscular Dystrophy; Dermatomyositis; Centronuclear Myopathy; Facioscapulohumeral Muscular Dystrophy; Myoshi Myopathy; Mitochondrial Myopathy; Nemaline Myopathy; Nonaka Myopathy; Myasthenia Gravis; and Polymyositis. Thus, among others, muscular dystrophies are neuromuscular disorders contemplated.

[0018] The methods result in an improvement in the human subject, for example, in absolute muscle specific force; force decrement during eccentric muscle contractions; serum CK level; serum cardiac troponin level; serum MMP9 level; grip strength; limb torque; limb mobility or flexibility; ambulation; 6 minute walk test; knee flexor or extensor strength; maximal voluntary isometric muscle contraction; North Star Ambulatory Assessment; muscle mass, fat reduction, or edema by limb T2-weighted MRI measures; muscle contractures; limb joint angle; heart function (heart rate, cardiac output, percent fractional shortening, stroke volume); respiration (including respiratory rate, blood oxygenation, need for supplemental oxygen); muscle necrosis; muscle regeneration; muscle wasting; muscle inflammation; muscle calcification; muscle central nucleation; muscle size or myofiber size; lifespan; and/or dystrophin or laminin alpha 2 surrogate protein expression (utrophin, plectin 1, laminin alpha 5, agrin).

[0019] Also provided herein are rAAV encoding a GALGT2 polypeptide such as the rAAVrh74.MCK.GALGT2.

Detailed Description

[0020] The present disclosure provides methods and products for treating neuromuscular disorders. The methods involve delivery of GALGT2 polynucleotides to muscle cells in a subject using AAV as a gene delivery vector. Subjects include, but are not limited to, mammals such as dogs, cats and humans. In some embodiments, the subjects are human patients. In some embodiments, the subjects are human pediatric patients.

[0021] In one aspect, methods are provided for the treatment of neuromuscular disorders comprising administering to a subject a recombinant AAV (rAAV) encoding GALGT2.

[0022] Neuromuscular disorders contemplated herein include, but are not limited to, a muscular dystrophy (MD). Neuromuscular disorders contemplated herein, also include neuromuscular disorders other than MDs. Thus, in some embodiments, neuromuscular disorders contemplated herein include, but are not limited to, Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy; Congenital Muscular Dystrophy (MDC) 1A, 1B, 1C and 1D; Limb Girdle Muscular Dystrophy (LGMD) 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 2A, 2B, 2C, 2D, 2E, 2F, 2G 2H, 2I, 2J, 2K, 2L, 2M, 2N, 2O and 2Q; Bethlem Myopathy; Ullrich Congenital Muscular Dystrophy; Muscle Eye Brain Disease; Fukuyama Congenital Muscular Dystrophy; Walker Warburg Syndrome; Myotonic Dystrophy; Myasthenic syndromes; Congenital Myasthenias; Inclusion Body Myopathy; Inclusion Body Myositis; Emery Dreifuss Muscular Dystrophy; Distal Muscular Dystrophy; Dermatomyositis; Centronuclear Myopathy; Facioscapulohumeral Muscular Dystrophy; Myoshi Myopathy; Mitochondrial Myopathy; Nemaline Myopathy; Nonaka Myopathy; Myasthenia Gravis; and Polymyositis. In some embodiments, the MD is DMD. In some embodiments, the MD is MDC1A. In some embodiments, the MD is LGMD2D.

[0023] In some embodiments of any of the methods described herein, the subject is at least 1 year of age (*e.g.*, at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20) or older. In some embodiments of any of the methods described herein, the subject is a male. In some embodiments of any of the methods described herein, the subject is a female. In some embodiments of any of the methods described herein, the subject is ambulant at the time of treatment. In some embodiments of any of the methods described herein, the subject is non-ambulant at the time that treatment begins. In some embodiments of any of the methods described herein, the subject is one having a confirmed mutation in the DMD gene using a clinically accepted technique that defines the mutation. Mutations in the dystrophin gene that give rise to a DMD phenotype are well known in the art, as are methods for identifying them in a subject. See, *e.g.*, the Leiden Duchenne muscular dystrophy mutation database, Leiden University Medical Center, The Netherlands, and Aartsma-Rus *et al.*, *Hum. Mut.*, 30:293-299 (2009).

[0024] In some embodiments of any of the methods described herein, the subject, by magnetic resonance imaging of the extensor digitorum brevis (EDB) muscle, exhibits a preservation of sufficient muscle mass to permit transfection or gene transfer. In some embodiments of any of the methods described herein, the subject is receiving a stable dose of corticosteroid therapy (*e.g.*, deflazacort, prednisone, or a generic form thereof), *e.g.*, for at least 4 (*e.g.*, 5, 6, 7, 8, 9, 10,

11, or 12) weeks prior to beginning treatment. In certain embodiments, the subject is on background steroid therapy (e.g., intermittent or chronic/continuous background steroid therapy). One of skill in the art would appreciate that such subjects are those who are subject to ongoing use of steroids (or corticosteroids) on top of which another treatment, such as the gene therapy described herein, is administered.

[0025] In some embodiments of any of the methods described herein, the subject is one that does not have an active viral infection. In some embodiments of any of the methods described herein, the subject the subject does not have a DMD mutation in the absence of weakness or loss of function. In some embodiments of any of the methods described herein, the subject does not exhibit symptoms of cardiomyopathy, such as dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lung. In some embodiments of any of the methods described herein, the subject does not, by echocardiogram, have an ejection fraction below about 40%. In some embodiments of any of the methods described herein, the subject is not one for whom serological evidence exists at the time of treatment of infection with HIV (since the subject may be in an immunocompromised state) or Hepatitis A, B, or C (since the subject may have transaminase elevation).

[0026] In some embodiments of any of the methods described herein, the subject has not been diagnosed, does not have, or is not being treated for an autoimmune disease. In some embodiments of any of the methods described herein, the subject does not have persistent leukopenia or leukocytosis (white blood cell count ≤ 3.5 K/ μ L or ≥ 20.0 K/ μ L) or an absolute neutrophil count < 1.5 K/ μ L.

[0027] In some embodiments of any of the methods described herein, the subject does not have a concomitant illness (e.g., viral infection or autoimmune disease) or requirement for chronic drug treatment that in the opinion of a medical practitioner creates an unnecessary risk for gene transfer.

[0028] In some embodiments of any of the methods described herein, the subject does not have an rAAVrh74 binding antibody titer of $\leq 1:400$ as determined by an ELISA immunoassay. In some embodiments of any of the methods described herein, the subject does not have an rAAVrh74 binding antibody titer of $\leq 1:50$ as determined by an ELISA immunoassay.

[0029] In some embodiments of any of the methods described herein, the subject does not have detectable circulating anti-Sda antibodies, e.g., as determined by ELISA immunoassay of a

biological sample of the subject [Blood groups: P, I, Sda, and Pr. AABB (1991)]. The Sda glycan is the human blood group structure made by GALGT2. The Sda blood group antigen is identical to the CT glycan structure made by GALGT2 in mice

[GalNAcb1,4[Neu5Aca2,3]Galb1,4GlcNAc-]. While the disclosure is not bound by any particular theory or mechanism of action, the presence or amount of the CT glycan structure is expected to be enhanced on cells expressing GALGT2 and the inventors believe that subjects with such Sda antibodies, estimated to be 0.2% of the subject population, may be at risk of antibody-mediated tissue rejection after rAAVrh74.MCK.GALGT2 treatment.

[0030] Suitable biological samples for use in the methods described herein include, e.g., any biological fluid. A biological sample can be, for example, a specimen obtained from a subject (e.g., a mammal such as a human) or can be derived from such a subject. A biological sample can be from a muscle biopsy. A biological sample can also be a biological fluid such as urine, whole blood or a fraction thereof (e.g., plasma or serum), saliva, semen, sputum, cerebrospinal fluid, tears, or mucus. A biological sample can be further fractionated, if desired, to a fraction containing particular analytes (e.g., proteins) of interest. For example, a whole blood sample can be fractionated into serum or into fractions containing particular types of proteins. If desired, a biological sample can be a combination of different biological samples from a subject such as a combination of two different fluids.

[0031] Biological samples suitable for the invention may be fresh or frozen samples collected from a subject, or archival samples with known diagnosis, treatment and/or outcome history. The biological samples can be obtained from a subject, e.g., a subject having, suspected of having, or at risk of developing, a cancer or an infection (e.g., a viral infection). Any suitable methods for obtaining the biological samples can be employed, although exemplary methods include, for example, open muscle biopsy, phlebotomy, swab (e.g., buccal swab), lavage, or fine needle aspirate biopsy procedure. Biological samples can also be obtained from bone marrow or spleen.

[0032] In some embodiments, a protein extract may be prepared from a biological sample. In some embodiments, a protein extract contains the total protein content. Methods of protein extraction are well known in the art. See, for example, Roe “Protein Purification Techniques: A Practical Approach”, 2nd Edition, Oxford University Press (2001). Numerous different and versatile kits can be used to extract proteins from bodily fluids and tissues, and are

commercially-available from, for example, BioRad Laboratories (Hercules, CA), BD Biosciences Clontech (Mountain View, CA), Chemicon International, Inc. (Temecula, CA), Calbiochem (San Diego, CA), Pierce Biotechnology (Rockford, IL), and Invitrogen Corp. (Carlsbad, CA).

[0033] Methods for obtaining and/or storing samples that preserve the activity or integrity of cells in the biological sample are well known to those skilled in the art. For example, a biological sample can be further contacted with one or more additional agents such as appropriate buffers and/or inhibitors, including protease inhibitors, the agents meant to preserve or minimize changes (*e.g.*, changes in osmolarity or pH) in protein structure. Such inhibitors include, for example, chelators such as ethylenediamine tetraacetic acid (EDTA), ethylene glycol tetraacetic acid (EGTA), protease inhibitors such as phenylmethylsulfonyl fluoride (PMSF), aprotinin, and leupeptin. Appropriate buffers and conditions for storing or otherwise manipulating whole cells are described in, for example, Pollard and Walker, “Basic Cell Culture Protocols,” Volume 75 of Methods in Molecular Biology, Humana Press (1997); Masters, “Animal cell culture: a practical approach,” Volume 232 of Practical Approach Series, Oxford University Press (2000); and Jones “Human cell culture protocols,” Volume 2 of Methods in Molecular Medicine, Humana Press (1996).

[0034] The methods of treating neuromuscular disorders disclosed herein result in transduction of muscle cells (*e.g.*, skeletal muscle, smooth muscle or cardiac muscle cells) with GALGT2 polynucleotide. An effective dose, or effective multiple doses, of a composition comprising a rAAV of the disclosure to a subject is a dose that prevents, slows progression of, or ameliorates (eliminates or reduces) muscle pathology associated with the neuromuscular disorder being treated. An effect on muscle pathology can be demonstrated by an improvement in one or more measures standard in the art such as: absolute muscle specific force; force decrement during eccentric muscle contractions; serum CK level; serum cardiac troponin level; serum MMP9 level; grip strength; limb torque; limb mobility or flexibility; ambulation; 6 minute walk test; knee flexor or extensor strength; maximal voluntary isometric muscle contraction; North Star Ambulatory Assessment; muscle mass, fat reduction, or edema by limb T2-weighted MRI measures; muscle contractures; limb joint angle; heart function (heart rate, cardiac output, percent fractional shortening, stroke volume); respiration (including respiratory rate, blood oxygenation, need for supplemental oxygen); muscle necrosis; muscle regeneration; muscle wasting; muscle inflammation; muscle calcification; muscle central nucleation; muscle size or

myofiber size; lifespan; and dystrophin or laminin alpha 2 surrogate protein expression (utrophin, plectin 1, laminin alpha 5, agrin). See, for example, Forbes *et al.*, *Radiology*, 269(1): 198-207 (2013); Govoni *et al.*, *Cell Mol. Life Sci.*, 70(23): 4585-4602 (2013); and Chandrasekharan and Martin, *Methods Enzymol.*, 479: 291-322 (2010). If a dose is administered prior to development of a neuromuscular disorder, the administration is prophylactic. If a dose is administered after the development of a neuromuscular disorder, the administration is therapeutic. The treatment of the subject by methods described herein is therefore contemplated to prevent, slow or prevent progression of, diminish the extent of, result in remission (partial or total) of, and/or prolong survival of a neuromuscular disorder.

[0035] In some embodiments, any of the methods described herein can further comprise detecting or measuring the level of expression of GALGT2 in cells transduced with the GALGT2 transgene. Methods for measuring mRNA or protein expression are well known in the art (e.g., immunoassays, such as Western blotting).

[0036] In some embodiments, any of the methods described herein can further comprise detecting or measuring the amount of CT antigen expressed on cells transduced with the GALGT2 polynucleotide [Chicoine *et al.*, *supra*].

[0037] In some embodiments, any of the methods described herein can further comprise detecting or measuring the amount of utrophin expressed on cells transduced with the GALGT2 polynucleotide [Chicoine *et al.*, *supra*].

[0038] In some embodiments, any of the methods described herein can further comprise detecting or measuring the number of fibers containing central nuclei, which fibers were transduced with the GALGT2 polynucleotide.

[0039] Routes of administration for the rAAV contemplated in the foregoing methods therefore include, but are not limited to, intraperitoneal (IP), intramuscular (IM) and intravascular [including, for example, inter-arterial limb perfusion (ILP) and intravenous (IV)] routes.

[0040] The dose of rAAV to be administered in methods disclosed herein will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be determined by methods standard in the art. More than one dose may be administered, for example, one, two, three or more doses.

Titers of rAAV in a dose may range from about 1×10^6 , about 1×10^7 , about 1×10^8 , about 1×10^9 , about 1×10^{10} , about 1×10^{11} , about 1×10^{12} , about 1×10^{13} , about 1×10^{14} , or to about 1×10^{15} or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg) (*i.e.*, 1×10^7 vg, 1×10^8 vg, 1×10^9 vg, 1×10^{10} vg, 1×10^{11} vg, 1×10^{12} vg, 1×10^{13} vg, 1×10^{14} vg, 1×10^{15} respectively). Methods for titering AAV are described in Clark *et al.*, *Hum. Gene Ther.*, 10: 1031-1039 (1999).

[0041] In some embodiments of the foregoing methods in which the route of administration is an IM route, the dose of the rAAV administered is from about 3×10^{11} to at least about 5×10^{12} vg/injection. (All ranges herein are intended to represent each individual value in the ranges, as well as the individual upper and lower values of each range.) In some embodiments of the foregoing methods in which the route of administration is an IM route, the dose of the rAAV administered is 3×10^{11} vg/injection. In some embodiments of the foregoing methods in which the route of administration is an IM route, the dose of the rAAV administered is 1×10^{12} vg/injection. In some embodiments of the foregoing methods in which the route of administration is an IM route, the dose of the rAAV administered is 5×10^{12} vg/injection.

[0042] In some embodiments of the foregoing methods in which the route of administration is an ILP route, the dose of the rAAV administered is from about 6×10^{12} to at least about 4.8×10^{13} vg/kg. (All ranges herein are intended to represent each individual value in the ranges, as well as the individual upper and lower values of each range.) In some embodiments of the foregoing methods in which the route of administration is ILP, the dose of the rAAV administered is 6×10^{12} vg/kg/limb. In some embodiments of the foregoing methods in which the route of administration is ILP, the dose of the rAAV administered is 1.2×10^{13} vg/kg/limb. In some embodiments of the foregoing methods in which the route of administration is ILP, the dose of the rAAV administered is 2.4×10^{13} vg/kg/limb. In some embodiments of the foregoing methods in which the route of administration is ILP, the dose of the rAAV administered is 4.8×10^{13} vg/kg/limb.

[0043] In some embodiments of the foregoing methods in which the route of administration is a systemic IV route, the dose of the rAAV administered is from about 2×10^{14} to at least about 6×10^{15} vg/kg. In some embodiments of the foregoing methods in which the route of administration is a systemic IV route, the dose of the rAAV administered is from about 4×10^{14} to at least about 6×10^{15} vg/kg. (All ranges herein are intended to represent each individual value in

the ranges, as well as the individual upper and lower values of each range.) In some embodiments of the foregoing methods in which the route of administration is systemic IV administration, the dose of the rAAV administered is 4×10^{14} vg/kg. In some embodiments of the foregoing methods in which the route of administration is systemic IV administration, the dose of the rAAV administered is 8×10^{14} vg/kg. In some embodiments of the foregoing methods in which the route of administration is systemic IV administration, the dose of the rAAV administered is 2×10^{15} vg/kg. In some embodiments of the foregoing methods in which the route of administration is systemic IV administration, the dose of the rAAV administered is 6×10^{15} vg/kg.

[0044] Human patients are subjects contemplated herein for treatment. Human patients are subjects contemplated herein for treatment by IM delivery. Such patients include those patients that, e.g.: (i) are 9 years of age or older, (ii) are male, (iii) are ambulant or non-ambulant; (iv) have a confirmed mutation in the DMD gene using a clinically accepted technique that defines the mutation; (v) by magnetic resonance imaging of the extensor digitorum brevis (EDB) muscle show a preservation of sufficient muscle mass to permit transfection or gene transfer; (vi) are of any ethnic group; (vii) have the ability to cooperate with all study procedures; (viii), if appropriate, and sexually mature and/or active, are willing to practice a reliable method of contraception; and/or (ix) are receiving a stable dose of corticosteroid therapy (e.g., deflazacort, prednisone, or a generic form thereof) for at least 12 weeks prior to gene transfer. Suitable patients may not include, e.g., those: (i) with active viral infections based on clinical observation; (ii) who have a DMD mutation without weakness or loss of function; (iii) with symptoms of cardiomyopathy, such as dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lung; (iv) who, by echocardiogram, have an ejection fraction below about 40%; (v) with serological evidence of infection with HIV or Hepatitis A, B, or C; (vi) who have or have been diagnosed as having (or are being treated for) an autoimmune disease; (vii) who have persistent leukopenia or leukocytosis (white blood cell count ≤ 3.5 K/ μ L or ≥ 20.0 K/ μ L) or an absolute neutrophil count < 1.5 K/ μ L; (viii) who have a concomitant illness or requirement for chronic drug treatment that in the opinion of a medical practitioner creates an unnecessary risk for gene transfer; (ix) who have an rAAVrh74 binding antibody titer of $\geq 1:400$ as determined by an ELISA immunoassay; or (x) have the presence of circulating anti-Sda antibodies. In an exemplary clinical protocol, DMD patients receive bilateral injections with one extensor digitorum brevis (EDB) muscle of each patient receiving the vector

rAAVrh74.MCK.GALGT2 and the other EDB muscle of each patient receiving saline alone. Subjects receive a dose of vector of 1×10^{12} vg (total dose).

[0045] Cell transduction efficiencies of the methods described above and below may be at least about 60, 65, 70, 75, 80, 85, 90, or 95 percent. In some embodiments involving IV limb perfusion delivery, transduction efficiency is increased by increasing the volume of the composition in which the rAAV is delivered, pre-flushing before delivery of the rAAV and/or increasing dwell time of the rAAV.

[0046] In another aspect, rAAV genomes are provided herein. The genomes of the rAAV administered comprise a GALGT2 polynucleotide under the control of transcription control sequences. The rAAV genomes lack AAV rep and cap DNA. AAV DNA in the rAAV genomes may be from any AAV serotype for which a recombinant virus can be derived including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11 and AAVrh.74. The nucleotide sequences of the genomes of these AAV serotypes are known in the art as noted in the Background Section above. In some embodiments, the AAV DNA in the rAAV genomes is from AAV rh.74. The polynucleotide sequence of the AAV rh.74 genome is set out in SEQ ID NO: 1, wherein nucleotides 210-2147 are the Rep 78 gene open reading frame, 882-208 are the Rep52 open reading frame, 2079-2081 are the Rep78 stop, 2145-2147 are the Rep78 stop, 1797-1800 are a splice donor site, 2094-2097 are a splice acceptor site, 2121-2124 are a splice acceptor site, 174-181 are the p5 promoter +1 predicted, 145-151 are the p5 TATA box, 758-761 are the p19 promoter +1 predicted, 732-738 are the p19 TATA box, 1711-1716 are the p40 TATA box, 2098-4314 are the VP1 Cap gene open reading frame, 2509-2511 are the VP2 start, 2707-2709 are the VP3 start and 4328-4333 are a polyA signal.

[0047] In some embodiments, the transcription control sequences of the rAAV genomes are muscle-specific control elements, including, but not limited to, those derived from the actin and myosin gene families, such as from the myoD gene family [See Weintraub et al., *Science*, 251: 761-766 (1991)], the myocyte-specific enhancer binding factor MEF-2 [Cserjesi and Olson, *Mol. Cell. Biol.*, 11: 4854-4862 (1991)], control elements derived from the human skeletal actin gene [Muscat et al., *Mol. Cell. Biol.*, 7: 4089-4099 (1987)], the cardiac actin gene, muscle creatine kinase (MCK) promoter [Johnson et al., *Mol. Cell. Biol.*, 9:3393-3399 (1989)] and the MCK enhancer, MHCK7 promoter (a modified version of MCK promoter that incorporates an

enhancer from myosin heavy chain [Salva *et al.*, *Mol. Ther.*, 15: 320-329 (2007)], desmin promoter, control elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene: hypoxia-inducible nuclear factors [Semenza *et al.*, *Proc. Natl. Acad. Sci. USA*, 88: 5680-5684 (1991)], steroid-inducible elements and promoters including the glucocorticoid response element (GRE) [See Mader and White, *Proc. Natl. Acad. Sci. USA*, 90: 5603-5607 (1993)], and other control elements. In some embodiments, the transcription control elements include the MCK promoter. In some embodiments, the transcription control elements include the MHCK7 promoter.

[0048] In some embodiments, the GALGT2 polynucleotide in a rAAV genome is the GALGT2 cDNA set out in Genbank Accession #AJ517771 (set out as nucleotides 1002-2522 of SEQ ID NO: 2). In some embodiments, the GALGT2 polynucleotide in a rAAV genome is the GALGT2 cDNA set out in Genbank Accession #AJ517771, or is a variant polynucleotide having 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the GALGT2 cDNA. In some embodiments, the variant GALGT2 polynucleotide encodes the same GALGT2 polypeptide as the polypeptide encoded by GALGT2 cDNA set out in Genbank Accession #AJ517771. The amino acid sequence of the GALGT2 polypeptide encoded by the GALGT2 cDNA set out in Genbank Accession #AJ517771 is set out in SEQ ID NO: 3. In some embodiments, the variant GALGT2 polynucleotide encodes a variant GALGT2 polypeptide with at least one amino acid sequence alteration as compared to the amino acid sequence of the polypeptide (SEQ ID NO: 3) encoded by GALGT2 cDNA set out in Genbank Accession #AJ517771. An amino acid sequence alteration can be, for example, a substitution, a deletion, or an insertion of one or more amino acids, preferably conservative substitutions. A variant GALGT2 polypeptide can have any combination of amino acid substitutions, deletions or insertions where the glycosyltransferase activity of the polypeptide is retained. In one aspect, a variant GALGT2 polypeptide can have a number of amino acid alterations such that its amino acid sequence shares at least 60, 70, 80, 85, 90, 95, 97, 98, 99 or 99.5% identity with the amino acid sequence (SEQ ID NO: 3) encoded by GALGT2 cDNA set out in Genbank Accession #AJ517771.

[0049] In some embodiments, the rAAV genome is the MCK.GALGT2 genome, the sequence of the GALGT2 gene cassette of which is set out in SEQ ID NO: 2 and is annotated as follows.

STARTING NUCLEOTIDE	ENDING NUCLEOTIDE	NAME	DESCRIPTION
------------------------	----------------------	------	-------------

53	230	5' ITR	Wild Type AAV2 inverted terminal repeat
236	442	MCK enhancer	Mouse muscle creatine kinase enhancer
443	793	MCK core promoter	Mouse muscle creatine kinase core promoter
794	846	Mu MCK Exon 1	Native transcriptional start site of exon 1 of mouse MCK gene (untranslated)
847	943	SV40 intron	SV40 late 16S/19S splice donor and acceptor sites
944	1000	5' untranslated region	5' untranslated region from plasmid pCMVb
1002	2522	Human GALGT2 cDNA	Human GALGT2 cDNA
2531	2579	Syn pA	Artificial polyadenylation signal
2581	2762	3' ITR	Wild Type AAV2 inverted terminal repeat

[0050] In yet another aspect, an isolated nucleic acid comprising the nucleotide sequence depicted in SEQ ID NO: 2 is provided. In some embodiments, the isolated nucleic acid consists of the nucleotide sequence depicted in SEQ ID NO: 2.

[0051] Also provided is an isolated nucleic acid comprising, in order from 5' to 3': (i) a first AAV2 inverted terminal repeat sequence (ITR); (ii) a muscle creatine kinase promoter sequence; (iii) a nucleotide sequence encoding a human GALGT2 polypeptide; and (iv) a second AAV2 ITR sequence, wherein the human GALGT2 polypeptide has an amino acid sequence that is at least 90% identical to SEQ ID NO:3, is 100% identical to SEQ ID NO:3, or is encoded by nucleotides 1002-2522 of SEQ ID NO: 2.

[0052] Recombinant AAV comprising the foregoing nucleic acids are contemplated as well as rAAV comprising a nucleotide sequence that is at least 90% identical to the nucleotide sequence depicted in SEQ ID NO:2.

[0053] DNA plasmids comprising rAAV genomes of the disclosure are provided. The DNA plasmids comprise rAAV genomes contemplated herein. The DNA plasmids are transferred to cells permissible for infection with a helper virus of AAV (*e.g.*, adenovirus, E1-deleted adenovirus or herpesvirus) for assembly of the rAAV genome into infectious viral particles. Techniques to produce rAAV particles, in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to a cell are standard in the art. Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from (*i.e.*, not in) the rAAV

genome, and helper virus functions. The AAV rep and cap genes may be from any AAV serotype for which recombinant virus can be derived and may be from a different AAV serotype than the rAAV genome ITRs, including, but not limited to, AAV serotypes AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11 and AAV rh74. Production of pseudotyped rAAV is disclosed in, for example, WO 01/83692. Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic *et al.*, *Molecular Therapy*, 22(11): 1900-1909 (2014).

[0054] A method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell. AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski *et al.*, 1982, *Proc. Natl. Acad. Sci. USA*, 79:2077-2081), addition of synthetic linkers containing restriction endonuclease cleavage sites (Laughlin *et al.*, 1983, *Gene*, 23:65-73) or by direct, blunt-end ligation (Senapathy & Carter, 1984, *J. Biol. Chem.*, 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV. Other examples of suitable methods employ adenovirus or baculovirus rather than plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells. Methods for producing rAAV with self-complementary genomes are also known in the art.

[0055] General principles of rAAV production are reviewed in, for example, Carter, 1992, *Current Opinions in Biotechnology*, 1533-539; and Muzyczka, 1992, *Curr. Topics in Microbial. and Immunol.*, 158:97-129). Various approaches are described in Ratschin *et al.*, *Mol. Cell. Biol.* 4:2072 (1984); Hermonat *et al.*, *Proc. Natl. Acad. Sci. USA*, 81:6466 (1984); Tratschin *et al.*, *Mol. Cell. Biol.* 5:3251 (1985); McLaughlin *et al.*, *J. Virol.*, 62:1963 (1988); and Lebkowski *et al.*, 1988 *Mol. Cell. Biol.*, 7:349 (1988). Samulski *et al.* (1989, *J. Virol.*, 63:3822-3828); U.S. Patent No. 5,173,414; WO 95/13365 and corresponding U.S. Patent No. 5,658,776 ; WO 95/13392; WO 96/17947; PCT/US98/18600; WO 97/09441 (PCT/US96/14423); WO 97/08298 (PCT/US96/13872); WO 97/21825 (PCT/US96/20777); WO 97/06243 (PCT/FR96/01064); WO 99/11764; Perrin *et al.* (1995) *Vaccine* 13:1244-1250; Paul *et al.* (1993) *Human Gene Therapy* 4:609-615; Clark *et al.* (1996) *Gene Therapy* 3:1124-1132; U.S. Patent. No. 5,786,211; U.S.

Patent No. 5,871,982; and U.S. Patent. No. 6,258,595. The foregoing documents are hereby incorporated by reference in their entirety herein, with particular emphasis on those sections of the documents relating to rAAV production.

[0056] In a further aspect, the disclosure thus provides packaging cells that produce infectious rAAV. In one embodiment packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line). In another embodiment, packaging cells are cells that are not transformed cancer cells, such as low passage 293 cells (human fetal kidney cells transformed with E1 of adenovirus), MRC-5 cells (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).

[0057] The rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for example, Clark et al., *Hum. Gene Ther.*, 10(6): 1031-1039 (1999); Schenpp and Clark, *Methods Mol. Med.*, 69 427-443 (2002); U.S. Patent No. 6,566,118 and WO 98/09657.

[0058] Thus, in another aspect, the disclosure contemplates a rAAV comprising a GALGT2 polynucleotide. In some embodiments, the rAAV comprises AAV rh74 capsid and a GALGT2 polynucleotide. In some embodiments, the genome of the rAAV lacks AAV rep and cap DNA. In some embodiments of the methods, the rAAV is rAAVrh74.MCK.GALGT2. In some embodiments, the rAAV is a self-complementary genome.

[0059] In another aspect, the disclosure contemplates compositions comprising a rAAV described herein. Compositions of the disclosure comprise rAAV in a pharmaceutically acceptable carrier. The compositions may also comprise other ingredients such as diluents. Acceptable carriers and diluents are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, pluronics or

polyethylene glycol (PEG). In some embodiments, the rAAV is formulated in Tris, MgCl₂, NaCl and pluronic F68. In some embodiments, the rAAV is formulated in 20 mM Tris (pH 8.0), 1 mM MgCl₂ and 200 mM NaCl containing 0.001% pluronic F68.

[0060] Combination treatments are also contemplated herein. Combinations as used herein include simultaneous treatment or sequential treatments. Combinations of methods of the disclosure with standard medical treatments (*e.g.*, corticosteroids and/or immunosuppressive drugs) are specifically contemplated, as are combinations with novel treatments. In various embodiments, subjects are treated with corticosteroids before, during or after (or with any permutation of combinations of two or more of the three possibilities), the subject is treated according to a method contemplated herein.

[0061] Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.


Examples

[0062] Thus, aspects and embodiments of the invention are illustrated by the following examples.

Example 1

[0063] A non-replicating rAAV termed rAAVrh74.MCK.GALGT2 was generated. The rAAV vector contains the complete human GALGT2 cDNA (Genbank Accession #AJ517771) under the control of a muscle creatine kinase promoter (MCK; a muscle specific promoter). A MCK promoter/enhancer sequence was used to drive muscle-specific gene expression and is composed of the mouse MCK core enhancer (206 bp) fused to the 351 bp MCK core promoter (proximal). After the core promoter, the 53 bp endogenous mouse MCK Exon1 (untranslated) is present for efficient transcription initiation, followed by the SV40 late 16S/19S splice signals (97 bp) and a small 5'UTR (61 bp). The intron and 5' UTR are derived from plasmid pCMV β (Clontech). The GALGT2 cassette has a consensus Kozak sequence immediately in front of the

ATG start and a small 53 bp synthetic polyA signal for mRNA termination. The human GALGT2 cassette was previously described by Martin *et al* (2009), *supra*. The only viral sequences included are the inverted terminal repeats (ITR) of AAV2, which are required for both viral DNA replication and packaging. The pAAVrh74.MCK.GALGT2 plasmid contains the human GALGT2 cDNA expression cassette flanked by AAV2 inverted terminal repeat (ITR) sequences. The gene cassette includes an MCK promoter, a chimeric intron with a Kozak sequence for optimizing gene expression, human GALGT2 coding sequences and a polyA signal. The sequence of the gene cassette with flanking AAV ITRs is set out in SEQ ID NO: 2.



[0064] The AAV vectors including the GALGT2 polynucleotides were produced by a modified cross-packaging approach in an adenovirus-free, triple plasmid DNA transfection (CaPO₄ precipitation) method in HEK293 cells [Rabinowitz *et al.*, *J. Virol.*, 76:791–801 (2002)]. Vector was produced by co-transfecting plasmid containing GALGT2 polynucleotide with an AAV helper plasmid rep2-cap rh.74 and an adenovirus helper plasmid in similar fashion as that previously described [Wang *et al.*, *Gene. Ther.*, 10:1528–1534 (2003)]. Plasmid rep2-cap rh.74 encodes the wild-type AAV2 rep gene and rh.74 cap gene, and the adenovirus helper plasmid (pAdhelper) expresses the adenovirus type 5 E2A, E4ORF6, and VA I/II RNA genes which are required for high-titer rAAV production.

[0065] Vectors were purified from clarified 293 cell lysates by sequential iodixanol gradient purification and anion-exchange column chromatography using a linear NaCl salt gradient as previously described [Clark *et al.*, *Hum. Gene Ther.*, 10:1031–1039 (1999)]. Vector genome (vg) titers were measured using QPCR based detection with a MCK specific primer/probe set and utilized the Prism 7500 Taqman detector system (PE Applied Biosystems) as previously described (Clark *et al.*, *supra*). Vector stock titers ranged between 1-40 x 10¹² vg/mL.

[0066] The vector is formulated in 20 mM Tris (pH 8.0), 1 mM MgCl₂ and 200 mM NaCl containing 0.001% pluronic F68. The vector is supplied as a frozen liquid that is thawed before clinical administration.

Example 2

IM delivery to subjects with DMD

[0067] Human patients are subjects contemplated herein for treatment by IM delivery. In an exemplary clinical protocol, DMD patients receive bilateral injections with one extensor digitorum brevis (EDB) muscle of each patient receiving the vector rAAVrh74.MCK.GALGT2 and the other EDB muscle of each patient receiving saline alone. Subjects in a first cohort receive a low dose of vector of 3×10^{11} vg (total dose). Subjects in a second cohort receive a higher dose of vector of 1×10^{12} vg (total dose).

[0068] Immediately prior to transportation to the clinical setting, appropriate dilutions of the vector are prepared. The dilution for the injection is 1:1 with normal saline. The vector is kept on ice (not frozen) until administration and is administered to the subject within 8 hours of preparation. Handling of rAAVrh74.MCK.GALGT2 follows compliance standards for Biosafety Level 1 vectors. See, www4.od.nih.gov/oba/RAC/guidelines_02/APPENDIX_G.htm#_Toc7246561.

[0069] Subjects have muscle weakness by clinical exam. The genetic diagnosis of DMD is established on the basis of a DMD gene mutation consistent with DMD, in the setting of an appropriate clinical history. In this study, all subjects are non-ambulant, having lost ambulation in an age range diagnostic of DMD (*i.e.*, less than 12 years old without steroid therapy, or less than 15 years old in the setting of longstanding steroid treatment). Subjects receive a stable dose of corticosteroid therapy (either prednisone or deflazacort, or their generic forms) for twelve weeks prior to treatment.

[0070] The vector or control is delivered via direct intramuscular injection into the extensor digitorum brevis (EDB) muscle of one foot of a subject, while the other foot receives saline alone. Conscious sedation is used on participants under 12 years of age. Patients over 12 years of age may receive conscious sedation or a sedative (like lorazepam) at least one hour prior to gene transfer. In addition, the skin over the gene transfer site is pre-treated with a lidocaine/prilocaine eutectic mixture incorporated in a cream base (EMLA cream) or a cellulose disk (EMLA patch). Comparable cream-based anesthesia such as xylocaine cream may be used. Procedures are performed under sterile conditions. The injection site is cleansed with three

successive applications of non-iodine containing surgical prep swabs and draped with disposable sterile drapes. A standard clinical Doppler ultrasound is used with a sterile sheath around the transducer to maintain asepsis of the injection field. For vector injections of rAAVrh74.MCK.GALGT2 or placebo to the EDB, disposable MyoJect Needles that enable simultaneous EMG recording and fluid injection are used to increase the precision of muscle injection. The anatomical midline point of the muscle is identified on the skin and 2 to 6 separate vector injections are distributed into the muscle. The injections are 0.5 cm in depth from the muscle surface. The total dose of vector is 3×10^{11} vg in 1.5 ml in the low dose group and 1×10^{12} vg in 1.5 ml in the high-dose group. The proximal and distal extent of vector delivery as determined by ultrasound is marked with an indelible radiographic marker for reference at the time of post-gene transfer muscle biopsy.

[0071] Subjects are followed with close monitoring of vital signs. Concomitant medications are monitored and documented after injection. Subjects are discharged two days after gene transfer (if no side effects are observed).

[0072] Subjects return for follow up visits. Muscle biopsies are conducted at day 45 or day 90. Immune studies at 45 and 75 days post-gene transfer and at 9, 12, 18, and 24 months include testing for binding antibody to rAAVrh74 and antibody to GALGT2, as well as ELISpot to detect T cell response to capsid antigens. Subjects are seen at the end of first and second years for a physical exam, strength testing and immune studies.

Example 3

Efficacy outcome measurements

[0073] Muscle biopsies are taken from EDB muscles. Samples are coded to maintain a blind in all subsequent analysis as to which was injected with rAAVrh74.MCK.GALGT2.

[0074] Efficacy outcome measures include: expression of GALGT2 as demonstrated with anti-CT epitope antibodies; GALGT2 protein expression quantified by western blot and assessed by densitometry; transduction efficiency measured by qPCR of the GALGT transgene from muscle, and expressed as vector genomes normalized to a genomic single-copy control; the number of fibers containing central nuclei compared between muscles by paired t-tests; and analyses will also include: Dystrophin expression (with antibodies to N-terminal, C-terminal, and rod domains), utrophin expression, and leukocyte markers including CD45, CD3, CD4, CD8,

and MAC 387. Muscle is examined for histological appearance. Antibodies to rAAVrh74 along with PBMC ELISpots to both rAAVrh74 capsid and GALGT protein are evaluated at different time points during the study up to two years. The muscle analysis of gene expression and inflammation is also done without breaking the blind.

[0075] Transgene expression is compared blindly between both EDB muscles from a single subject, and between those subject's biopsies at day 45 or day 90. A vector-specific primer probe set is used to amplify a unique 5' untranslated leader sequence of the transgene that will distinguish transgene expressed GALGT2 protein from endogenous GALGT2. Quantification of protein is done using direct immunofluorescence (IF) and Western blot (WB) studies of muscle tissue. CD4+ and CD8+ mononuclear cells are quantified by immunostaining and reported as number of cells/mm² area. MHC I and MHC II antigen expression are assessed on muscle sections. Muscle morphometrics are also performed, including fiber size histograms and quantification of central nucleation. Analysis also includes PCR analysis for viral DNA.

[0076] Immune responses are assessed by IFN- γ ELISpots to GALGT2 and AAV capsid. A rise in IFN- γ of > 2SD to either virus or transgene is considered significant. An additional measure of immune response is the binding antibody assay to AAV.

[0077] Measurements for improvements in one or more of absolute muscle specific force; force decrement during eccentric muscle contractions; serum CK level; serum cardiac troponin level; serum MMP9 level; grip strength; limb torque; limb mobility or flexibility; ambulation; 6 minute walk test; knee flexor or extensor strength; maximal voluntary isometric muscle contraction; North Star Ambulatory Assessment; muscle mass, fat reduction, or edema by limb T2-weighted MRI measures; muscle contractures; limb joint angle; heart function (heart rate, cardiac output, percent fractional shortening, stroke volume); respiration (including respiratory rate, blood oxygenation, need for supplemental oxygen); muscle necrosis; muscle regeneration; muscle wasting; muscle inflammation; muscle calcification; muscle central nucleation; muscle size or myofiber size; lifespan; and dystrophin or laminin alpha 2 surrogate protein expression (utrophin, plectin 1, laminin alpha 5, agrin) are among those contemplated. See, for example, Forbes *et al.*, *Radiology*, 269(1): 198-207 (2013); Govoni *et al.*, *Cell Mol. Life Sci.*, 70(23): 4585-4602 (2013); and Chandrasekharan and Martin, *Methods Enzymol.*, 479: 291-322 (2010).

[0078] For each of the measures, statistical analysis based on differences between pre- and post-gene transfer examinations (clinical, or on muscle biopsy) will be analyzed using a paired t test, with a p value of < 0.05 indicating significance.

Example 4

Vascular delivery by isolated limb perfusion

[0079] A vascular delivery route termed isolated limb perfusion (ILP) is also contemplated for treatment of human patients. Multiple leg muscles can be targeted by ILP via delivery through the femoral artery. The method permits isolation of the limb from the general circulation, increasing transduction efficiency and preventing virus from escaping to the general circulation. [Rodino-Klapac et al., *Mol. Ther.*, 18: 109-117 (2010)]. An exemplary clinical protocol is set out below.

[0080] The rAAVrh74.MCK.GALGT2 is prepared as described in Examples 1 and 2.

[0081] The subject receives a stable dose of corticosteroid therapy (either prednisone or deflazacort, or their generic forms) for twelve weeks prior to treatment. Prednisone treatment is also continued after gene transfer. The sedated and anesthetized subject is secured to a surgical bed. Proximal and distal tourniquets are loosely positioned above the knee and below the gastrocnemius muscle of a macaque. A small incision is placed at the femoral triangle and the femoral artery is identified and dissected free and looped with proximal and distal ligatures to control bleeding and facilitate catheter introduction. The femoral artery is cannulated with a 3.0 Fr introducer sheath via a modified Seldinger method by passing the pre-flushed sheath over a wire previously placed in the artery. The sheath is advanced only a few centimeters and secured in place with a 3.0 braided silk suture.

[0082] Following sheath placement in the femoral arteries and veins, 100-200 u/kg of unfractionated heparin is administered and allowed to circulate for 3-5 minutes. A Choice PT coronary guide wire is then placed initially into the right femoral vein and artery, and then ultimately into the left femoral vein and artery. A 4-mm diameter Tyshak Mini Balloon catheter is passed through the 3.3-French sheath through the right femoral artery into position in the femoral iliac artery junction. An 8-mm diameter x 2 cm long Tyshak Mini Balloon catheter is passed through the 4-French sheath into appropriate position in the right femoral-iliac vein

junction. Small hand injections of diluted contrast are performed to confirm appropriate blockage of both the left femoral artery and the right femoral vein. If needed, sheaths and balloons can be exchanged for larger sizes. For example, the 4-French sheath in the right femoral vein can be exchanged for a 6-French sheath and a 12 mm x 2 cm long Tyshak II Balloon catheter can be passed over the Choice PT guidewire into appropriate position. Small hand injections through the side arm of the sheath are performed to confirm location and complete occlusion of the femoral vein.

[0083] A pre-flush of 2 mL/kg of Ringer's lactate heparinized solution is infused after both right femoral artery and femoral venous balloons are inflated, with isolation of the right leg. After 1 minute, the Ringer's lactate flush at 2 mL/kg is completed. Next, the rAAVrh74.MCK.GALGT2 vector is infused at a dose of between 2×10^{12} vg/kg/limb and 4.8×10^{13} vg/kg/limb in a volume of 8 mL/kg LR over 1-1/2 minutes (since bilateral limb perfusion is performed, leading to a total patient dose of between 4×10^{12} vg/kg and 9.6×10^{13} vg/kg). After the rAAVrh74.MCK.GALGT2 is delivered, there is 10 minutes of dwell time, and then the right femoral arterial sheath is then used to infuse 2 mL/kg of heparinized Ringer's lactate over 1 minute. The balloons are then deflated, and the catheters and guidewires are removed.

[0084] The left leg is then targeted for the same procedure. The left femoral artery is maintained with 3.3-French sheaths. Again, using a 4-mm diameter Tyshak Mini Balloon catheter in the left femoral artery over the Choice PT coronary guidewire, as well as the 12 mm x 2 cm long Tyshak II Balloon catheter through the 5-French sheath in the left femoral vein with inflations up to 3 atmospheres of pressure, appropriate occlusion is demonstrated. The infusion protocol is repeated with 2 mL/kg of heparinized Ringer's lactate infused over 1 minute, and a dose of between 2×10^{12} vg/kg/limb and 4.8×10^{13} vg/kg/limb of rAAVrh74.MCK.GALGT2 is infused over 1 minute and 15 seconds, with the dwell time of 10 minutes. Finally, 2 mL/kg of heparinized Ringer's lactate is infused through left femoral arterial sheath, and then the sheaths are removed from all 4 access sites with pressure hemostasis and a HemCon patch.

[0085] Variations of this protocol can be used to deliver rAAVrh74.MCK.GALGT2 via other arteries to alternative groups of muscles as needed. For example, delivery via the phrenic, intercostal and/or subcostal arteries to supply the diaphragm muscle, or delivery via the coronary arteries to supply the heart are contemplated. Similar doses would be utilized for each

procedure, and that multiple procedures might be done in a single patient or even in a single patient admission.

[0086] At the completion of dosing the tourniquets and catheter are removed and direct pressure is applied to the wound for 10 min to control bleeding. The wound is closed with a continuous subcuticular 4.0 Vicryl suture. A pressure dressing is applied to the site and kept in place until the subject awoke from anesthesia.

[0087] Following the ILP vector delivery protocol, subject follow up and efficacy outcome measurements/analyses similar to that described above for the IM-treated subjects are conducted.

Example 5

Systemic Vascular Delivery

[0088] Another contemplated route of delivery of the rAAVrh74.MCK.GALGT2 vector to muscle is systemic vascular delivery. An exemplary dose escalation study examining efficacy can be conducted as follows.

[0089] Determination of dose range

[0090] IV injection (via the tail vein) of 1.4×10^{15} vg/kg rAAVrh74.MCK.GALGT2 at day 1 of age causes transduction of over 90% of all limb skeletal muscles in a wild type mouse, including tibialis anterior, gastrocnemius, quadriceps and triceps, and the same does leads to over 50% transduction of all cardiomyocytes in the wild type mouse heart and over 70% of cardiomyocytes in the heart of mdx model mice heart. Notably, analysis of overall mdx mouse heart function at 3 months after treatment, relative to mock-treated mdx control animals, showed almost a doubling of cardiac output as the result of rAAVrh74.MCK.GALGT2 treatment with this dose of vector, either with or without stimulation with dobutamine, a beta agonist that stimulates heart rate. Thus, there is an 80% increase in blood flow from the dystrophin-deficient heart after rAAVrh74.MCK.GALGT2 treatment when vector is given prior to the onset of disease-related cardiac pathology. 5×10^{15} vg/kg is contemplated to be the maximal therapeutic dose to transduce all heart and skeletal muscle cells throughout the entire body using intravenous injection. Thus, it is contemplated that a dose range of about 5×10^{13} vg/kg to about 5×10^{15} vg/kg would cover the minimally effective dose and the optimally effective dose for rAAVrh74.MCK.GALGT2 treatment of the whole patient in a clinical IV study.

[0091] Protocol

[0092] The rAAVrh74.MCK.GALGT2 is prepared as described in Examples 1 and 2.

[0093] The subject is started on prophylactic enteral prednisolone (glucocorticoid) (approximately 1 mg/kg/day) one day prior to the rAAVrh74.MCK.GALGT2 administration. Prednisone treatment is also continued after gene transfer.

[0094] On the day of gene transfer (Day 0) prior to rAAVrh74.MCK.GALGT2 infusion, a physical exam is performed with vitals collected.

[0095] If a subject appears inadequately hydrated in the judgment of the PI, bolus(es) of 10-20 mL/kg normal saline may be given during the time between hospital admission and gene transfer. Subjects maintain their usual diet until eight hours prior to gene transfer, after which they have no solid food; clear liquids are allowed up until two hours prior to gene transfer, after which they will be fully NPO. They resume their usual PO intake after they return to pre-sedation baseline. Gene transfer will be performed under sterile conditions, under light to moderate sedation under the direction of a qualified anesthesiologist. Sedation may vary, but the subject can be sedated using inhaled nitrous prior to induction with propofol via an IV, and maintained with inhaled sevoflurane or a propofol drip. In those subjects who, in the opinion of the PI (and in consultation with the anesthesiologist), are determined to not need sedation in order to safely deliver the vector, sedation may be deferred.

[0096] All subjects in the trial receive an intravenous injection of rAAVrh74.MCK.GALGT2 via peripheral limb vein. The dose range contemplated is between 5×10^{13} vg/kg and 5×10^{15} vg/kg.

[0097] As one example, each vector dose is given undiluted, divided into 50 mL or less, to fill Becton Dickinson 60 mL capacity polypropylene syringes, prepared by the NCH Investigational Drug Pharmacy. The vector salt solution is approximately 400 mOsmol/L. Infusion is performed using a Smiths Medical Medfusion 4000 Syringe Infusion Pump with PharmGuard Infusion Management Software Suite, delivered via a Smiths Medical MX563 infusion tube. The infusion rate is not to exceed 2 ml/kg/min for any subject. The infusion is given over approximately 10 to 20 minutes. The vector is flushed from the infusion tubing using normal saline at the end of the infusion. It is contemplated that vector doses can be divided and administered differently as necessary.

[0098] Subjects are closely monitored for side effects during the infusion, including continuous heart rate, respiratory rate, and pulse oximetry; and intermittent blood pressure

monitoring. Heart rate, respiratory rate, pulse oximetry, temperature, and blood pressure are measured before and immediately after the infusion, and every five minutes during the infusion, and repeated at 15 minutes post-infusion.

[0099] Subjects remain in an intensive care unit bed following gene transfer and remain admitted to the hospital for 48 hours after gene transfer. Vital signs are obtained hourly for 4 hours following the injection and then every 4 hours until discharge. Transfer out of intensive care may be undertaken after the initial 24 hours of post-infusion monitoring, if the PI has no concerns.

[00100] Following the vector delivery protocol, subject follow up and efficacy outcome analyses similar to that described above for the IM-treated subjects are conducted.

[00101] While the present invention has been described in terms of specific embodiments, it is understood that variations and modifications will occur to those skilled in the art. Accordingly, only such limitations as appear in the claims should be placed on the invention.

[00102] All documents referred to in this application are hereby incorporated by reference in their entirety with particular attention to the content for which they are referred. Also, this application claims the benefit of the filing date of U.S. Provisional Application Nos. 62/220,107 filed September 17, 2015; 62/221,068 filed September 20, 2015 and 62/301,260 filed February 2016; which are incorporated by reference in their entirety herein.

Claims

We claim:

1. A nucleic acid comprising, in order from 5' to 3':
 - (i) a first AAV2 inverted terminal repeat sequence (ITR);
 - (ii) an MCK enhancer comprising nucleotides 236-442 of SEQ ID NO: 2;
 - (iii) a muscle creatine kinase core promoter sequence set out in nucleotides 443-793 of SEQ ID NO: 2;
 - (iv) a nucleotide sequence encoding a human GALGT2 polypeptide comprising nucleotides 1002-2522 of SEQ ID NO: 2; and
 - (v) a second AAV2 ITR sequence.
2. The nucleic acid of claim 1 further comprising 3' to said core promoter, a mouse MCK exon 1 sequence set out in nucleotides 794-846 of SEQ ID NO: 2.
3. The nucleic acid of any one of claims 1-2 further comprising 3' to said core promoter, an SV40 intron sequence set out in nucleotides 847-943 of SEQ ID NO: 2.
4. The nucleic acid of any one of claims 1-3 further comprising 3' to said core promoter, a 5' untranslated region set out in nucleotides 944-1000 of SEQ ID NO: 2.
5. The nucleic acid of any one of claims 1-4 further comprising 3' to said nucleotide sequence encoding a human GALGT2 polypeptide, a Syn pA sequence set out in nucleotides 2531-2579 of SEQ ID NO: 2.
6. The nucleic acid of any one of claims 1-5,
wherein said first ITR is set out in nucleotides 53-230 of SEQ ID NO: 2, and/or
wherein said second ITR is set out in nucleotides 2581-2762 of SEQ ID NO: 2.
7. The nucleic acid of claim 6,
wherein said first ITR is set out in nucleotides 53-230 of SEQ ID NO: 2; and
wherein said second ITR is set out in nucleotides 2581-2762 of SEQ ID NO: 2.

8. A nucleic acid comprising an rAAV.rh74.MCK.GALGT2 genome that is at least 90% identical to the nucleotide sequence set out in SEQ ID NO: 2.

9. A nucleic acid comprising the rAAV.rh74.MCK.GALGT2 genome set out in SEQ ID NO: 2.

10. A recombinant adeno-associated virus particle (rAAV) comprising the nucleic acid of any one of claims 1-9, wherein the rAAV is infectious.

11. The rAAV of claim 10, wherein the rAAV is serotype AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-10, AAV-11, or AAVrh.74.

12. The rAAV of claim 10 or 11, wherein the AAV DNA in the rAAV genome is from AAV rh.74.

13. The rAAV of any one of claims 10-12, wherein the polynucleotide sequence of the AAV rh.74 genome is set out in SEQ ID NO: 1.

14. A composition comprising the rAAV of any one of claims 10-13 and a pharmaceutically acceptable carrier.

15. Use of the composition of claim 14 in the manufacture of a medicament for the treatment of a neuromuscular disorder, wherein the neuromuscular disorder is Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy; Congenital Muscular Dystrophy (MDC) 1A, 1B, 1C and 1D; Limb Girdle Muscular Dystrophy (LGMD) 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, 2A, 2B, 2C, 2D, 2E, 2F, 2G 2H, 2I, 2J, 2K, 2L, 2M, 2N, 2O and 2Q; Bethlem Myopathy; Ullrich Congenital Muscular Dystrophy; Muscle Eye Brain Disease; Fukuyama Congenital Muscular Dystrophy; Walker Warburg Syndrome; Myotonic Dystrophy; Myasthenic syndromes; Congenital Myasthenias; Inclusion Body Myopathy; Inclusion Body Myositis; Emery Dreifuss Muscular Dystrophy; Distal Muscular Dystrophy; Dermatomyositis; Centronuclear Myopathy; Facioscapulohumeral Muscular Dystrophy; Myoshi Myopathy;

Mitochondrial Myopathy; Nemaline Myopathy; Nonaka Myopathy; Myasthenia Gravis; or Polymyositis.

16. Use of the composition of claim 14 in the manufacture of a medicament for the treatment of a neuromuscular disorder, wherein the neuromuscular disorder is a muscular dystrophy.

17. The use of claim 16, wherein the muscular dystrophy is Duchenne Muscular Dystrophy.

18. The use of claim 16, wherein the muscular dystrophy is Congenital Muscular Dystrophy 1A.

19. The use of claim 16, wherein the muscular dystrophy is Limb Girdle Muscular Dystrophy 2D.

20. The use of any one of claims 15-19, wherein the composition is formulated for intramuscular (IM), isolated limb infusion or perfusion (ILP), or intravenous (IV) administration.

21. The use of claim 20 which is formulated for IM administration.

22. The use of claim 20 or 21 comprising a dose of the rAAV from 3×10^{11} to at least 5×10^{12} vg/injection.

23. The use of claim 20 which is formulated for infusion or ILP administration.

24. The use of claim 20 or 23 comprising a dose of the rAAV from 2×10^{12} to at least 4.8×10^{13} vg/kg/limb, or a total dose of from 4×10^{12} to at least 9.6×10^{13} .

25. The use of claim 20 which is formulated for IV administration.

26. The use of claim 20 comprising a dose of the rAAV from 2×10^{14} to at least 6×10^{15} vg/kg.
27. The use of claim 20 comprising a dose of the rAAV from 5×10^{13} vg/kg to 5×10^{15} vg/kg.